Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04620915 · ClinicalTrials.gov registry record · NA

Construal Level as a Novel Pathway for Affect Regulation and Cancer Control

A NA study of Cancer and Smoking Cessation, sponsored by University of Oregon.

Active
Registry status
NA
Development phase
300
Enrollment target
2
Study locations

NCT04620915 is a NA study of Cancer and Smoking Cessation that is active but no longer recruiting, run by University of Oregon. The registered enrollment target is 300 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04620915, a NA study of Cancer and Smoking Cessation, is active but no longer recruiting, sponsored by University of Oregon.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
2
Study locations

Study Summary

The objective of the proposed research is to conduct a longitudinal experiment on the neurocognitive pathways and individual differences in high-level construal for affect regulation and smoking cessation. The population is adult smokers aged 25-55 who have tried and failed to quit and who are experiencing poverty. The primary endpoints are (a) the similarity in neural representation of high-level construal to one of two candidate pathways, (b) the presence of meaningful individual differences in the neural representation of high-level construal, and (c) as a secondary endpoint, the effect size of the high-level construal condition on smoking as measured by cigarettes per day. Each of these endpoints corresponds to a specific null hypothesis. The null hypothesis for the first endpoint is that high-level construal is not significantly different in its neural representation from down-regulation of craving, which would suggest that high-level construal does not operate through distinct mechanisms from traditional treatments. The null hypothesis for the second endpoint is that the between-subjects variability in the neural representation of construal level does not significantly relate to relevant individual differences measures (e.g., traits, task behavior), which would suggest that individual differences are not meaningfully related to outcomes. Finally, the null hypothesis for the secondary endpoint is that the magnitude of the effect of high-level construal on smoking as measured by reductions in average cigarettes per day is not significantly greater than in the other conditions, which would suggest that the efficacy of the high-level construal condition is not significantly greater than a standard text-messaging intervention. The primary endpoints will be assessed at baseline and change from pre-to-post training (8 weeks).

Interventions

  • BEHAVIORAL High-level construal
  • BEHAVIORAL Down-regulation of craving for cigarettes
  • BEHAVIORAL Up-regulation of goal energization

Study Locations (2)

Oregon

  • University of Oregon, Lewis Integrative Sciences Building - Eugene
  • University of Oregon, Social and Affective Neuroscience Laboratory - Eugene

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2021-10-11
Est. Completion 2025-12-30
Phase NA

Sponsor

University of Oregon

63 total trials

What the Registry Record Tells You About NCT04620915

The ClinicalTrials.gov registry entry for NCT04620915 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower). The listed sponsor is University of Oregon, which has 63 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which High-level construal is the first listed.

NCT04620915 reports 2 study locations spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT04620915 about?

NCT04620915 is a clinical study titled "Construal Level as a Novel Pathway for Affect Regulation and Cancer Control". The objective of the proposed research is to conduct a longitudinal experiment on the neurocognitive pathways and individual differences in high-level construal for affect regulation and smoking cessation. The population is adult smokers aged 25-55 who have tried and failed to quit and who are exper...

What is the current status of trial NCT04620915?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2021-10-11. Estimated completion is 2025-12-30.

What conditions does trial NCT04620915 study?

This clinical trial studies the following conditions: Cancer, Smoking Cessation, Smoking Reduction.

What interventions are being tested in trial NCT04620915?

The interventions under investigation include: High-level construal (BEHAVIORAL), Down-regulation of craving for cigarettes (BEHAVIORAL), Up-regulation of goal energization (BEHAVIORAL).

Who is sponsoring clinical trial NCT04620915?

This trial is sponsored by University of Oregon, which has 63 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04620915 being conducted?

This trial has 2 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.